Cargando…
Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain
Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030932/ https://www.ncbi.nlm.nih.gov/pubmed/35455404 http://dx.doi.org/10.3390/ph15040407 |
_version_ | 1784692265150578688 |
---|---|
author | Jung, Young-Hwan Kim, Yeo Ok Kang, Koon Mook Lee, Hyung Gon Son, Borum Han, Xuehao Oh, Eunseok Kim, Siwon Seo, Seon Hee Park, Jong-Hyun Park, Ki Duk Kim, Woong Mo Yoon, Myung Ha Kim, Yong-Chul |
author_facet | Jung, Young-Hwan Kim, Yeo Ok Kang, Koon Mook Lee, Hyung Gon Son, Borum Han, Xuehao Oh, Eunseok Kim, Siwon Seo, Seon Hee Park, Jong-Hyun Park, Ki Duk Kim, Woong Mo Yoon, Myung Ha Kim, Yong-Chul |
author_sort | Jung, Young-Hwan |
collection | PubMed |
description | Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (μ) and kappa (κ) opioid receptors. The most advanced hybrid of these multifunctional compounds, 17, exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC(50) values of 70 nM, 154 nM and 2.01 μM at hSERT, hNET and hDAT, respectively. Additionally, compound 17 showed partial agonism (EC(50) = 384 nM) at the μ-opioid receptor with no influence at the κ-opioid receptor. In in vivo pain animal experiments, the multifunctional compound 17 showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain. |
format | Online Article Text |
id | pubmed-9030932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90309322022-04-23 Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain Jung, Young-Hwan Kim, Yeo Ok Kang, Koon Mook Lee, Hyung Gon Son, Borum Han, Xuehao Oh, Eunseok Kim, Siwon Seo, Seon Hee Park, Jong-Hyun Park, Ki Duk Kim, Woong Mo Yoon, Myung Ha Kim, Yong-Chul Pharmaceuticals (Basel) Article Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (μ) and kappa (κ) opioid receptors. The most advanced hybrid of these multifunctional compounds, 17, exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC(50) values of 70 nM, 154 nM and 2.01 μM at hSERT, hNET and hDAT, respectively. Additionally, compound 17 showed partial agonism (EC(50) = 384 nM) at the μ-opioid receptor with no influence at the κ-opioid receptor. In in vivo pain animal experiments, the multifunctional compound 17 showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain. MDPI 2022-03-27 /pmc/articles/PMC9030932/ /pubmed/35455404 http://dx.doi.org/10.3390/ph15040407 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jung, Young-Hwan Kim, Yeo Ok Kang, Koon Mook Lee, Hyung Gon Son, Borum Han, Xuehao Oh, Eunseok Kim, Siwon Seo, Seon Hee Park, Jong-Hyun Park, Ki Duk Kim, Woong Mo Yoon, Myung Ha Kim, Yong-Chul Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain |
title | Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain |
title_full | Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain |
title_fullStr | Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain |
title_full_unstemmed | Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain |
title_short | Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain |
title_sort | development of dibenzothiazepine derivatives as multifunctional compounds for neuropathic pain |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030932/ https://www.ncbi.nlm.nih.gov/pubmed/35455404 http://dx.doi.org/10.3390/ph15040407 |
work_keys_str_mv | AT jungyounghwan developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT kimyeook developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT kangkoonmook developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT leehyunggon developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT sonborum developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT hanxuehao developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT oheunseok developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT kimsiwon developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT seoseonhee developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT parkjonghyun developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT parkkiduk developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT kimwoongmo developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT yoonmyungha developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain AT kimyongchul developmentofdibenzothiazepinederivativesasmultifunctionalcompoundsforneuropathicpain |